<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="54835">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02392286</url>
  </required_header>
  <id_info>
    <org_study_id>1501015143</org_study_id>
    <nct_id>NCT02392286</nct_id>
  </id_info>
  <brief_title>Corticosteroid Dosage for Crohn's Disease Flare</brief_title>
  <official_title>A Prospective, Randomized Trial Comparing the Efficacy of Body-weight Based Versus Fixed Corticosteroid Dosage on Remission in Patients With Moderate to Severe Crohn's Disease Flares</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective randomized comparative effectiveness trial designed to compare fixed dosing and
      weight-based dosing of corticosteroids in patients with Crohn's disease flares.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Determine if weight-based corticosteroid (1mg/kg daily) induces remission at a greater
           rate than fixed corticosteroid dosage.

        -  Determine if weight-based corticosteroid is associated with greater rate of adverse
           events than fixed corticosteroid dosage.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients in remission at end of 2 weeks</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with response at end of 2 weeks</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with response or remission at end of 1 week</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with response or remission at end of 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with response or remission at end of 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corticosteroid-associated side effects</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">182</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Weight-based</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Corticosteroid dose fixed at equivalent to 40mg prednisone daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid</intervention_name>
    <description>Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.</description>
    <arm_group_label>Weight-based</arm_group_label>
    <arm_group_label>Fixed dose</arm_group_label>
    <other_name>Prednisone</other_name>
    <other_name>Methylprednisolone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18

          -  Established diagnosis of Crohn's disease

          -  Diagnosis of Crohn's flare

          -  Decision by treating gastroenterologist to start corticosteroid therapy

        Exclusion Criteria:

          -  Patients in whom corticosteroid therapy is contraindicated: immunocompromised (active
             cancer on chemotherapy or radiation treatment), severe liver disease (decompensated
             cirrhosis, active alcoholic hepatitis), end-stage renal disease on dialysis, AIDS or
             AIDS-defining illness; myocardial infarction within the past year; NYHA Class 4 heart
             failure

          -  Patients on systemic corticosteroid therapy currently or within the past 8 weeks

          -  Patients not on stable doses of immunomodulators or biologics for at least 8 weeks

          -  Infectious colitis (e.g., C. difficile, CMV, HSV)

          -  Systemic infections (bacteremia, fungal infections)

          -  Fulminant Crohn's disease

          -  Patients who require imminent surgery

          -  Abscess

          -  Pregnancy

          -  Weight &lt;35 kg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loren Laine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University, Section of Digestive Diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Loren Laine, MD</last_name>
    <email>loren.laine@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sunhee Park, MD</last_name>
    <email>sunhee.park@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale-New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loren Laine, MD</last_name>
      <email>loren.laine@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sunhee Park, MD</last_name>
      <email>sunhee.park@yale.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 11, 2016</lastchanged_date>
  <firstreceived_date>March 12, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Loren Laine</investigator_full_name>
    <investigator_title>Professor of Medicine, Digestive Diseases</investigator_title>
  </responsible_party>
  <keyword>Corticosteroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
